The SAMe-TT₂R₂ score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation

References

• Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719–2747.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):2246–2280.
   Web of Science ®Google Scholar
• Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher? Thromb Haemost. 2015 Jun;113(6):1165–1169.
   PubMed Web of Science ®Google Scholar
• Senoo K, Lau YC, Lip GY. Updated NICE guideline: management of atrial fibrillation (2014). Expert Rev Cardiovasc Ther. 2014 Sep;12(9):1037–1040.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011 Nov;106(5):968–977.
   PubMed Web of Science ®Google Scholar
• Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest. 2001 Jan;119(1 Suppl):194S–206S.
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on Thrombosis–task force on anticoagulants in heart disease. Thromb Haemost. 2013 Dec;110(6):1087–1107.
   PubMed Web of Science ®Google Scholar
• Sanfélix-Gimeno G, Rodríguez-Bernal CL, Hurtado I, et al. Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. BMJ Open. 2015;5(10):e007613.
   Web of Science ®Google Scholar
• Jurcuţ R, Militaru S, Geavlete O, et al. Predictive factors for obtaining a correct therapeutic range using antivitamin K anticoagulants: a tertiary center experience of patient adherence to anticoagulant therapy. Patient Prefer Adherence. 2015;9:1271–1278.
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Chao T-F. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost. 2015 Jun;113(6):1170–1173.
   PubMed Web of Science ®Google Scholar
• Lip GY. Atrial fibrillation and stroke prevention: brief observations on the last decade. Expert Rev Cardiovasc Ther. 2014 Apr;12(4):403–406.
   PubMedGoogle Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2013 May;15(5):625–651.
   Google Scholar
• Eikelboom JW, Weitz JI. “Real world” use of non-vitamin K antagonist oral anticoagulants (NOACs): lessons from the Dresden NOAC registry. Thromb Haemost. 2015 Jun;113(6):1159–1161.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Poli D, Olshansky B. The SAMe-TT2R2 score and quality of anticoagulation in AF: can we predict which patient benefits from anticoagulation? Thromb Haemost. 2015 Sep 30;114(4):657–659.
   PubMed Web of Science ®Google Scholar
• Rietbrock S, Plumb JM, Gallagher AM, et al. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. Thromb Haemost. 2009 Mar;101(3):527–534.
   PubMed Web of Science ®Google Scholar
• Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11;349(11):1019–1026.
   PubMed Web of Science ®Google Scholar
• Van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006 May;129(5):1155–1166.
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001;119(1 Suppl):22S–38S.
   PubMed Web of Science ®Google Scholar
• Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333(1):11–17.
   PubMed Web of Science ®Google Scholar
• Van Den Ham HA, Klungel OH, Leufkens HGM, et al. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost. 2013 Jan;11(1):107–115.
   PubMed Web of Science ®Google Scholar
• Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009 May;124(1):37–41.
   PubMed Web of Science ®Google Scholar
• Sjögren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113(6):1370–1377.
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Cannegieter SC, Van Der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239.
   PubMed Web of Science ®Google Scholar
• Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003 Jun;15(3):213–216.
   PubMed Web of Science ®Google Scholar
• Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84–91.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Angoulvant D, Lip GYH. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace. 2015 May;17(5):671–673.
   PubMed Web of Science ®Google Scholar
• Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet. 1998 Nov 7;352(9139):1505–1509.
   PubMed Web of Science ®Google Scholar
• Anguita Sánchez M, Bertomeu Martínez V, Cequier Fillat Á, CALIFA study researchers. Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Esp Cardiol (Engl Ed). 2015 Sep;68(9):761–768.
   PubMed Web of Science ®Google Scholar
• Roldán V, Marín F. The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thromb Haemost. 2015 Apr;113(4):671–673.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, Jjv M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–989.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther. 2014;8:789–798.
   PubMed Web of Science ®Google Scholar
• Lau YC, Lip GYH. Which drug should we use for stroke prevention in atrial fibrillation? Curr Opin Cardiol. 2014 Jul;29(4):293–300.
   PubMed Web of Science ®Google Scholar
• Proietti M, Lip GYH. Simple decision making between a vitamin K antagonist and non-vitamin K antagonist oral anticoagulant (NOACs): using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):150–152.
   PubMedGoogle Scholar
• Azoulay L, Dell’Aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J. 2014;35(28):1881–1887.
   PubMed Web of Science ®Google Scholar
• Lip GYH. Stroke prevention in atrial fibrillation: changing concepts. Eur Heart J Cardiovasc Pharmacother. 2015 Apr 1 [cited 2015 Aug 5];1(2):76–79.
   Google Scholar
• Skeppholm M, Friberg L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol. 2014 Dec;103(12):998–1005.
   PubMed Web of Science ®Google Scholar
• Menéndez-Jándula B, Souto JC, Oliver A, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med. 2005 Jan 4;142(1):1–10.
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest. 2013 Nov;144(5):1555–1563.
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 Dec 5;347(23):1825–1833.
   PubMed Web of Science ®Google Scholar
• Poli D, Antonucci E, Testa S, et al. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med. 2014 Jun;9(4):443–447.
   PubMed Web of Science ®Google Scholar
• Skov J, Bladbjerg E-M, Bor MV, et al. SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest. 2014 Jan;145(1):187–188.
   PubMed Web of Science ®Google Scholar
• Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014 Nov;127(11):1083–1088.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014 Sep;146(3):719–726.
   PubMed Web of Science ®Google Scholar
• Abumuaileq RR-Y, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace. 2015 May;17(5):711–717.
   PubMed Web of Science ®Google Scholar
• Roldán V, Cancio S, Gálvez J, et al. The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective “real-world” inception cohort study. Am J Med. 2015 Nov; 128(11):1237–1243.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortiz M, Bertomeu V, Cequier Á, et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost. 2015 Sep 30;114(4):695–701.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. Jama. 2015;313(19):1950–1962.
   PubMed Web of Science ®Google Scholar
• Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2(1):e000067.
   Web of Science ®Google Scholar
• Apostolakis SZ, Konstantinides SV. Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens. Clin Res Cardiol Suppl. 2013 Jan;1(8):38–45.
   Google Scholar
• Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. Jama. 2012;307(18):1952–1958.
   PubMed Web of Science ®Google Scholar
• Tomita H, Kadokami T, Momii H, et al. Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients. Thromb Res. 2013;132(5):537–542.
   PubMed Web of Science ®Google Scholar
• Volgman AS, Manankil MF, Mookherjee D, et al. Women with atrial fibrillation: greater risk, less attention. Gend Med. 2009 Sep;6(3):419.
   PubMed Web of Science ®Google Scholar
• Vallurupalli S, Deshmukh A, Paydak H. Gender based differences in benefit from novel oral anticoagulant drugs compared to warfarin in atrial fibrillation: an analysis of published studies. J Am Coll Cardiol. 2014;63:12_S.
   PubMed Web of Science ®Google Scholar
• Wang K-L, Chiang C-E. Optimal international normalized ratio for atrial fibrillation in Asians and Japanese: do we really know? Circ J. 2013;77(9):2242–2243.
   PubMed Web of Science ®Google Scholar